Cite
HARVARD Citation
Pignata, S. et al. (n.d.). 987PTrabectedin plus pegylated liposomal doxorubicin (PLD) in patients with platinum-sensitive recurrent ovarian cancer (PSROC) regardless of prior use of antiangiogenics: First results of an observational, prospective study. Annals of oncology. p. . [Online].